7.08
+0.07(+1.00%)
Currency In USD
| Previous Close | 7.01 |
| Open | 6.91 |
| Day High | 7.23 |
| Day Low | 6.78 |
| 52-Week High | 7.51 |
| 52-Week Low | 2.12 |
| Volume | 3.23M |
| Average Volume | 2.64M |
| Market Cap | 706.09M |
| PE | -10.26 |
| EPS | -0.69 |
| Moving Average 50 Days | 5.07 |
| Moving Average 200 Days | 3.62 |
| Change | 0.07 |
If you invested $1000 in Aquestive Therapeutics, Inc. (AQST) since IPO date, it would be worth $441.12 as of October 19, 2025 at a share price of $7.08. Whereas If you bought $1000 worth of Aquestive Therapeutics, Inc. (AQST) shares 5 years ago, it would be worth $1,315.99 as of October 19, 2025 at a share price of $7.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
GlobeNewswire Inc.
Oct 08, 2025 11:00 AM GMT
New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis WARREN,
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a